Is This Biotech Stock a Bad News Buy?
Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. The drugmaker has encountered many headwinds related to its controversial Alzheimer's disease drug, Aduhelm. Recapping the entire Aduhelm saga would take far more space than we have here.